Since the paper by Holtz in 1933 (1) there has appeared in the German literature a considerable number of articles on a photochemical derivative of ergosterin, designated dihydrotachysterol or A.T. 10 (antitetanisches Priiparat Nr. 10). Until recently this substance has not been available in this country. One gets the impression from the German literature (see below) that A.T. 10 and vitamin D effect calcium metabolism in much the same way with the one extraordinary difference that A.T. 10 is not antirachitic. This combination of facts is most surprising since at first thought it is hard to believe that any substance, chemically so closely related to vitamin D, could have so similar an action on calcium metabolism and still not cure rickets. It thus becomes of interest to know the exact manner in which this new substance effects calcium and phosphorous metabolism and wherein its action differs from that of vitamin D. No complete metabolic data have as yet appeared. Therefore the present investigations were undertaken. They consist of calcium and phosphorus metabolic studies on 3 cases of hypoparathyroidism treated with A.T. 10, two of whom were later treated with vitamin D for comparison.' Patients with hypoparathyroidism were chosen for this study so that secondary changes in calcium and phosphorus metabolism resulting from varying degrees of activity of the patient's own parathyroid tissue would not be confused with changes due to the A.T. 10. The importance of this aspect was discussed in a paper concerned with the action of vitamin D (2) .
REVIEW OF LITERATURE
Bamburger (3) , von Wendt (4) , and Windaus (5) were the first to suggest that the toxic effect and anti- rachitic effect of irradiated ergosterin were owing to two different factors. The previous conception had been that the toxic manifestations-calcium deposits in various organs and hypercalcemia-were due to an overabundance of the antirachitic factor-hence, a hypervitaminosis. This toxic factor was called by Holtz et al. (6) the " Calcinosefaktor " to differentiate it from the antirachitic factor. Holtz, Gissel, and Rossmann (7) studied the various derivatives of ergosterin. It was found (7, 8) that upon irradiation of ergosterin with ultraviolet light one obtained the following substances: ergosterin, lumisterin, tachysterin, vitamin D, toxisterin, suprasterin I, and suprasterin II. Of these, tachysterin, vitamin D, and toxisterin contained the "Calcinosefaktor"; vitamin D alone, contained the antirachitic factor. Holtz conceived the idea that the " Calcinosefaktor " might be made use of in treating the hypocalcemia of hypoparathyroidism. To this end tachysterin was converted chemically into dihydrotachysterol, A.T. 10, to render it suitable for peroral administration.
A method of standardizing the toxic effect of ergosterin derivatives has been worked out (7) . The unit of toxicity is designated the " Toxische Grenzdosis " (T.G.) and is that amount which given to mice for 12 days will cause a weight loss of at least 12 per cent. It is therefore possible to compare the antirachitic and the toxic properties of various preparations. Harnapp Numerous papers state that A.T. 10 is not antirachitic and it seems that this fact must have been ascertained on animals. The protocols of such experiments have not been found. Harnapp (9) , however, found that A.T. 10 had no effect in curing infantile rickets or in raising the serum calcium level in such cases. Bomskov (10) , on the other hand, found that A.T. 10 therapy will raise the serum calcium level in spasmophilia, but agrees that it will not correct the underlying rickets. Eckert (10) found A.T. 10 effective in late rickets. Dr. Alfred Shohl at the Children's Hospital in Boston in some preliminary and as yet unpublished experiments found that A.T. 10 was not antirachitic in rats.
The literature leaves no doubt that A.T. 10 is very effective for the treatment of hypoparathyroidism (11 to 31 inclusive). Reschke as quoted by Rieder (17) stated in 1934 that 200 cases had been treated without a single failure. Holtz (19) cited one patient who had been taking A.T. 10 for 3 years without any ill effect. Another patient died of acute yellow atrophy after taking the drug for 2 years (340 cc. of A.T. 10 in all) and at autopsy showed no evidence of calcification of the kidneys. It has also been used with benefit in tetany due to sprue (17, 18) .
The dosage varies with the individual. Holtz (19) (29) . The cataracts, so commonly seen in conjunction with hypoparathyroidism, can be kept from developing, but are not influenced by the drug once they have formed (10, 18, 19, 33) .
The drug has been used with apparently good results in conditions other than those associated with hypocalcemia. These include hemophilia (17, 18, 34, 35) , impetigo herpetiformis (10), peripheral circulatory conditions (36) , and a variety of other conditions. Kappis as quoted by Rieder (18) treated " coeliakie." Gissel (35) reported good results using A.T. 10 in the treatment of bronchial asthma as well as in drug and serum eruptions. Wendt (38) . The fecal calcium excretion is decreased (38, 39) . Jordans (30) and Holtz and Kramer (38) , furthermore, found that if a low calcium diet is used, calcium will be mobilized from the skeleton. Hoff (40) in one case of hypoparathyroidism found a slight elevation in the serum phosphorus level after treatment followed by a later fall. Snapper (14) and Arnold and Blum (26) found a lowering of the serum phosphorus level following treatment. Otherwise no data have been found on the phosphorus metabolism. Halbertsma (27) mentioned a mobilization of calcium with an increase in the calcium level of the blood, but with no increase in the serum phosphorus level. Hoff (40) observed a slight rise in serum magnesium, no decided change in serum potassium, and a slight rise in the "alkali reserves'" with A.T. 10 therapy. Holtz (10) could not confirm the changes in the alkali reserve. Arnold, Holtz, and Marx (32) found the action of A.T. 10 antagonized by estrin and the male sex hormone.
Experiment I
The subject, W. C., Patient 3, Number 14,727, of the first investigation (2) was a 16 year old boy with severe idiopathic hypoparathyroidism. A detailed clinical history will appear elsewhere (42) .
The experiment was divided into Parts A and B. In Part A he received A.T. 10, in Part B he received crystalline vitamin D. Sufficient time was allowed to elapse between the two parts of the experiment so that his metabolic levels would return to the pretherapeutic values. Throughout the entire experiment he received a diet of an exactly similar composition each day. This consisted of a low calcium, moderately high phosphorus diet. In addition, 0.45 of a gram of calcium in the form of calcium gluconate was given daily by mouth in three divided doses. Thus, it was thought, sufficient calcium and phosphorus was being ingested to give the drug something to act upon if its action were on the absorption of calcium or phosphorus. The data are shown in Figure 1 and Table IA and Table IB. During the three control periods (Periods 1, 2, and 3) there were present a low serum calcium level (7.0 mgm. per 100 cc.), a high serum phos- From this experiment alone one would suspect that there are two primary metabolic effects of A.T. 10 (decrease of fecal calcium and increase of urinary phosphorus); that each of these lead to a secondary effect (rise in serum calcium and fall in serum phosphorus); and finally that one of these secondary effects (rise in serum calcium) in turn leads to a tertiary effect (increase in urinary calcium excretion).
When one turns to the second part of the experiment (Table IB) , one finds the fecal calcium values in the control periods (Periods 11, 12, and 13) considerably higher than those in similar periods (Periods 1, 2, and 3) in the first half of ary calcium excretion rises. There is also a delayed fall in the fecal phosphorus excretion, suggesting that eventually the body compensates for the increased urinary phosphate excretion by an increased absorption of phosphorus.
It will be noted that all the changes were in the same direction as when A.T. 10 was administered.8 There were, however, certain quantitative differences. The effect of vitamin D in the doses used was slower in coming on; on the other hand, the effect, once there, remained longer after discontinuance of treatment. Secondly, if one confines ones attention to the two primary effects (to decrease the fecal calcium and to increase the urinary phosphorus), it will be noted that vitamin D in the doses used effected fecal calcium as efthat of A.T. 10, whereas the effect of vitamin D on the urinary phosphorus excretion was decidedly less than that of A.T. 10.
Experiment II
The subject, D. B., Number 8568, of the second investigation, was a girl of 21 with severe Figure 2 and Tables IIA and IIB 6 O_ than she would have had with a serum calcium value of 6.9 mgm., had she not been receiving intravenous calcium medication. The excess (about 180 mgm.) undoubtedly resulted from the calcium given intravenously. It is of further interest that slightly more calcium was excreted in fecal phosphorus excretion, although not nearly large enough to account for the increased urinary phosphorus excretion.
There was a rise in urinary calcium excretion greater than the fall in fecal calcium excretion so that the calcium balance was decreased and even the feces than was given by mouth. This confirms the work of Nicolayson (43) that the fecal calcium does not merely represent unabsorbed calcium in the diet.
During the periods of A.T. 10 administration (Periods 4 and 5) the fecal calcium excretion was decreased as in the previous experiment but not by more than the calcium in the diet.
Again, as in Experiment I, A.T. 10 had a very marked effect (about 100 per cent) on the urinary phosphorus excretion with the production of a negative phosphorus balance. In this experiment, however, there was a slight decrease in the became negative during Periods 6 and 7. This demonstrates that calcium can be mobilized from the skeleton with A.T. 10.
In Part B it is seen that again the effect of vitamin D was qualitatively the same as that of A.T. 10. The data again suggest that the action of vitamin D is slower and lasts longer. On the whole, it seems fair to conclude also that the ratio of the action of A.T. 10 on the urinary phosphorus excretion to that of its action on calcium absorption was greater with A.T. 10 than with vitamin D. In comparing Parts A and B in this respect, allowance must be made for the fact that Experiment III The subject, M. F. McC., Number 48512, of this experiment was a woman of 40 with severe postoperative hypoparathyroidism, for which she had been followed at the Massachusetts General Hospital since March, 1930 . The value fell from 8.6 mgm. to 6.1 mgm. There was a slight decrease in the fecal calcium excretion and a slight rise in the urinary calcium excretion. The net result was that the calcium balance was little affected while the phosphorus balance was made negative. These findings strengthen the observations made in the previous experiments.
DISCUSSION
In a previous paper (2) the tentative hypothesis was made that there are two fundamental actions of vitamin D-to increase calcium absorption and to increase urinary phosphorus excretion. A.T. 10 has both of these properties, but the ratio of the effect on phosphorus excretion to that on calcium absorption is apparently greater with A.T. 10 than with vitamin D (Figure 3 ). Since the calcium absorption effect is obviously an antirachitic one whereas the phosphate excretion effect would work in the opposite direction, some explanation is afforded as to why A.T. 10 is not antirachitic.
Since one of the main actions of A.T. 10 appears to be to increase the excretion of urinary phosphorus and since the theory has been advanced that this is the fundamental action of the parathyroid hormone (44) it becomes of interest to compare the metabolic action of A.T. 10 with that of the parathyroid hormone. A priori one would expect them to be the same except for the fact that A.T. 10 has an additional action in causing increased calcium absorption. In Table IV , data are given on the effect of the parathyroid hormone on the calcium and phosphorus metabolism of the same individual with postoperative hypoparathyroidism studied in Experiment III. During the control periods (Periods 20, 21, 22, and 23), the patient had a positive balance of both calcium and phosphorus; the serum calcium was 8.9 mgm. per 100 cc. and the serum phosphorus was 6.9 mgm. per 100 cc. Up to the onset of the experiment the patient had been receiving large amounts of vitamin D which explains why the serum calcium was as high as it was (Table III) .
With administration of parathormone in Period an additional action on calcium metabolism which the parathyroid hormone does not possess (Figure 4) . This is constructed similarly to Figure 3 (q.v.). It is designed to show the difference between the effect of the parathyroid hormone on fecal Ca and urinary P excretions and that of A.T. 10 .
The chart is constructed from the data in Tables III and IV . It will be noted that both A.T. 10 and the parathyroid hormone have a similar effect on urinary P excretion. The fecal calcium excretion in the parathormone experiment, however, showed no constant variations. The large fluctuations were to be expected because of the large Ca intake in that experiment. A.T. 10 on the other hand probably did have a definite effect on fecal calcium (although one would not be sure from this experiment above).
calcium excretion in the urine. The findings fit the hypothesis that the fundamental action of the parathyroid hormone on phosphorus metabolism is the same as that of A.T. 10 while A.T. 10 has In a previous paper (2) the following diagram was presented to show the main actions of vitamin D on calcium and phosphorus metabolism and the sequelae of these actions: 10 as regards its property of causing a markedly increased urinary phosphorus excretion but differed in that it probably had no primary action on calcium absorption from the gut.
5. Because of the similarity between the actions of the parathyroid hormone and of A.T. 10, the latter drug is a most efficacious therapeutic agent in the treatment of hypoparathyroidism.
